National Cancer Plan

Andrew Murrison Excerpts

Tuesday 4th February 2025 Commons Chamber

[Andrew Gwynne]

My hon. Friend makes a very good point, and it relates to not just cancer but a whole range of conditions, including cardiovascular disease, strokes and so many others—it is the same areas that have the worst outcomes, because there are endemic health inequalities that we have not shifted the dial on for decades. Life expectancy is much lower, and healthy life expectancy is much worse, than in less deprived areas. It is part of our health mission to drive forward better health outcomes for people living in the poorest areas, and our national cancer plan will be a key part of that.

[Dr Andrew Murrison (South West Wiltshire) (Con)]

In his remarks yesterday, the Minister for Data Protection and Telecoms, the hon. Member for Rhondda and Ogmore (Chris Bryant), implied that he was discussing the future with AstraZeneca, which has had some bad news this week. AstraZeneca makes immunotherapies, among other things, and therefore is very important in allowing people to live better for longer. What discussion will the Minister be having as part of his plan with the pharmaceutical sector, since plainly the national health service cannot do this alone?

[Andrew Gwynne]

The right hon. Gentleman makes a very good point. I have certainly had a number of roundtables with the pharmaceutical sector in the UK about how we can support it, how we can grow our life sciences sector and how Britain can be at the cutting edge of new treatments and clinical trials. Indeed, we had a Delegated Legislation Committee yesterday on regulations to make it easier to carry out clinical trials in this country. Some of the latest advances in pharma are quite remarkable; I think particularly of the work being done on mRNA technology to look at having specific cancer treatments pertinent to a person’s genomics—it could be a game changer.